600056 中国医药
已收盘 12-19 15:00:00
资讯
新帖
简况
中国医药12月19日主力资金流出2860万元 连续5日减仓
市场透视 · 12-19 15:18
中国医药12月19日主力资金流出2860万元 连续5日减仓
中国医药控股股东筹划2%股权无偿划转 已获国资委批准
财中社 · 12-18 18:59
中国医药控股股东筹划2%股权无偿划转 已获国资委批准
中国医药12月17日主力资金流出2828万元 连续3日减仓
市场透视 · 12-17 15:18
中国医药12月17日主力资金流出2828万元 连续3日减仓
中国医药被告了，涉案5.1亿元
医药之梯 · 12-16
中国医药被告了，涉案5.1亿元
中国医药(600056.SH)：注射用哌拉西林钠拟中选集中采购
智通财经 · 12-13
中国医药(600056.SH)：注射用哌拉西林钠拟中选集中采购
中国医药最新公告：子公司产品拟中选第十批全国药品集中采购
证券之星 · 12-13
中国医药最新公告：子公司产品拟中选第十批全国药品集中采购
【券商聚焦】野村料中国医药行业明年首季增速可回升 看好百济神州(06160)及药明合联(02268)
金吾财讯 · 12-12
【券商聚焦】野村料中国医药行业明年首季增速可回升 看好百济神州(06160)及药明合联(02268)
野村料中国医药行业明年首季及上半年收入增速可回升
阿斯达克财经 · 12-12
野村料中国医药行业明年首季及上半年收入增速可回升
中国医药：公司股票今日收涨。公司目前生产经营活动正常
证券之星 · 12-11
中国医药：公司股票今日收涨。公司目前生产经营活动正常
中国医药12月05日主力资金流出2061万元 连续3日减仓
市场透视 · 12-05
中国医药12月05日主力资金流出2061万元 连续3日减仓
中国医药最新公告：子公司天方药业获得磷酸奥司他韦胶囊药品注册证书
证券之星 · 12-04
中国医药最新公告：子公司天方药业获得磷酸奥司他韦胶囊药品注册证书
中国医药(600056.SH)：磷酸奥司他韦胶囊获药品注册批件
智通财经 · 12-04
中国医药(600056.SH)：磷酸奥司他韦胶囊获药品注册批件
新康界：2024年1-8月中国医药零售市场药品销售规模达到3244亿元 同比增长1.4%
智通财经 · 12-03
新康界：2024年1-8月中国医药零售市场药品销售规模达到3244亿元 同比增长1.4%
中国医药最新公告：子公司天方药业获得药品补充申请批准通知书
证券之星 · 12-02
中国医药最新公告：子公司天方药业获得药品补充申请批准通知书
中国医药(600056.SH)子公司盐酸托莫西汀胶囊通过仿制药一致性评价
智通财经 · 12-02
中国医药(600056.SH)子公司盐酸托莫西汀胶囊通过仿制药一致性评价
中国医药12月02日主力资金流入982万元 连续3日加仓
市场透视 · 12-02
中国医药12月02日主力资金流入982万元 连续3日加仓
中国医药(600056.SH)：胞磷胆碱钠注射液通过仿制药一致性评价
智通财经网 · 11-29
中国医药(600056.SH)：胞磷胆碱钠注射液通过仿制药一致性评价
中国医药最新公告：子公司天方药业胞磷胆碱钠注射液通过仿制药一致性评价
证券之星 · 11-29
中国医药最新公告：子公司天方药业胞磷胆碱钠注射液通过仿制药一致性评价
中国医药最新公告：重要参股公司筹划变更实际控制人事项获得重庆市国资委批复
证券之星 · 11-28
中国医药最新公告：重要参股公司筹划变更实际控制人事项获得重庆市国资委批复
1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会
汇添富基金 · 11-28
1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会
加载更多
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司建立了以国际贸易为引领、以医药工业为支撑、以医药商业为纽带的贸、工、技、服一体化产业格局，全面推动工商贸三大业务板块业务整合，积极发挥协同优势。主要产品有原料药、制剂药、中成药、医药商业、国际贸易。公司在中国物流与采购联合会医疗器械供应链分会发布的“2023年中国医疗器械供应链百强企业”中位列第5位；在“2023年中国医疗器械SPD运营服务商重点企业”中位列第11位。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":11.65,"timestamp":1734591600000,"preClose":11.7,"halted":0,"volume":15993304,"delay":0,"floatShares":1495000000,"shares":1496000000,"eps":0.6024,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.05,"latestTime":"12-19 15:00:00","open":11.5,"high":11.69,"low":11.47,"amount":185000000,"amplitude":0.0188,"askPrice":11.65,"askSize":180,"bidPrice":11.64,"bidSize":686,"shortable":0,"etf":0,"ttmEps":0.6024,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":11.7,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":12.87,"lowLimit":10.53,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"pbRate":1.5,"roa":"--","roe":"3.83%","epsLYR":0.7006,"committee":0.294219,"marketValue":17427000000,"floatMarketCap":17421000000,"peRate":19.339309,"changeRate":-0.0043,"turnoverRate":0.0107,"status":1},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2492129805","title":"中国医药12月19日主力资金流出2860万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492129805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492129805?lang=zh_cn&edition=full","pubTime":"2024-12-19 15:18","pubTimestamp":1734592694,"startTime":"0","endTime":"0","summary":"12月19日, 中国医药股价跌0.43%，报收11.65元，成交金额1.85亿元，换手率1.07%，振幅1.88%，量比0.63。中国医药今日主力资金净流出2860万元，连续5日净流出，上一交易日主力净流出3133万元，今日环比减少8.71%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为33.33%，平均跌幅为0.84%。该股近5个交易日下跌5.67%，主力资金累计净流出1.51亿元；近20日主力资金累计净流出3.49亿元，其中净流出天数为15日。净流出前三个股分别为老百姓、重药控股、中国医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219153152a1fa9002&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219153152a1fa9002&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0175","BK0188","BK0250","BK0010","600056","BK0185","BK0082"],"gpt_icon":0},{"id":"2492138640","title":"中国医药控股股东筹划2%股权无偿划转 已获国资委批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2492138640","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492138640?lang=zh_cn&edition=full","pubTime":"2024-12-18 18:59","pubTimestamp":1734519591,"startTime":"0","endTime":"0","summary":"财中社12月18日电中国医药 发布关于重要参股公司筹划变更实际控制人事项的进展公告。此次变更获得了国家市场监督管理总局的反垄断不实施进一步审查决定书，以及重庆市国资委的批复。截至2024年12月18日，公司已收到通用技术集团的告知函，国务院国资委同意此次2%股权的无偿划转。2024年前三季度，中国医药实现收入261亿元，归母净利润4.47亿元。文章来源：财中社中国医药控股股东筹划2%股权无偿划转，已获国资委批准","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218191920a1f86581&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218191920a1f86581&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0250","BK0010","BK0185","600056","BK0188","BK0175","BK0028","BK0082"],"gpt_icon":0},{"id":"2492939626","title":"中国医药12月17日主力资金流出2828万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492939626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492939626?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:18","pubTimestamp":1734419892,"startTime":"0","endTime":"0","summary":"12月17日, 中国医药股价跌1.52%，报收11.70元，成交金额2.21亿元，换手率1.26%，振幅1.77%，量比0.62。中国医药今日主力资金净流出2828万元，连续3日净流出，上一交易日主力净流出2435万元，今日环比增加16.14%。该股近5个交易日下跌1.76%，主力资金累计净流出8066万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3.22亿元，其中净流出天数为14日。净流出前三个股分别为老百姓、瑞康医药、中国医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217152158ab7e6f6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217152158ab7e6f6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0082","600056","BK0188","BK0175","BK0028","BK0185","BK0250","BK0010"],"gpt_icon":0},{"id":"2491664091","title":"中国医药被告了，涉案5.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491664091","media":"医药之梯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491664091?lang=zh_cn&edition=full","pubTime":"2024-12-16 19:49","pubTimestamp":1734349740,"startTime":"0","endTime":"0","summary":"（二）原告王一兵于被告中国医药健康产业股份有限公司支付上述股权转让款后十日内配合被告中国医药健康产业股份有限公司将其持有的河北通用医药有限公司30%的股权变更到被告名下。案件受理费 259.18 万元，由被告中国医药健康产业股份有限公司负担。中国医药表示，截至本公告披露日，本案一审判决尚未生效，公司正在积极准备上诉，最终结果存在不确定性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-16/doc-inczsfyp2481842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0175","600056","BK0188","BK0082","BK0010","BK0250","BK0185"],"gpt_icon":0},{"id":"2491323241","title":"中国医药(600056.SH)：注射用哌拉西林钠拟中选集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491323241","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491323241?lang=zh_cn&edition=full","pubTime":"2024-12-13 19:13","pubTimestamp":1734088425,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药 发布公告，2024年12月12日，公司下属子公司海南通用三洋药业有限公司参加了第十批全国药品集中采购的投标。根据联合采购办公室发布的全国药品集中采购拟中选结果公示显示，三洋药业注射用哌拉西林钠拟中选本次集中采购。三洋药业本次拟中选的注射用哌拉西林钠2023年度营业收入2,881.91万元，2024年上半年度营业收入1,335.49万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0250","BK0185","600056","BK0082","BK0028","BK0010","BK0188"],"gpt_icon":0},{"id":"2491323427","title":"中国医药最新公告：子公司产品拟中选第十批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2491323427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491323427?lang=zh_cn&edition=full","pubTime":"2024-12-13 19:09","pubTimestamp":1734088188,"startTime":"0","endTime":"0","summary":"中国医药公告，下属子公司三洋药业参加了第十批全国药品集中采购的投标。根据联合采购办公室发布的全国药品集中采购拟中选结果公示显示，三洋药业注射用哌拉西林钠拟中选本次集中采购。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300038212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0082","600056","BK0185","BK0175","BK0250","BK0010","BK0188"],"gpt_icon":0},{"id":"2490825750","title":"【券商聚焦】野村料中国医药行业明年首季增速可回升 看好百济神州(06160)及药明合联(02268)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825750","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490825750?lang=zh_cn&edition=full","pubTime":"2024-12-12 12:22","pubTimestamp":1733977355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 野村中国医药保健行业研究部主管张佳林指，今年中国医疗市场仍面对困境，等待复苏。展望未来，他指，有不少企业近年致力于拓展海外市场，同时近期以来国家医保局多次公开探讨商业健康险发展，对创新药普及有帮助。张佳林预计，在低基数及潜在需求逐步释放下，明年首季及上半年行业收入增长将重新加快，看好GLP-1新药及抗体偶联药物ADC等前景，又指行业估值处于较低水平，亦为未来的反弹提供基础，在生物科技股中较看好百济神州(06160)，认为其海外市场特别是美国地区销售表现强劲，而在CRO板块则看好药明合联(02268)的高增长潜力及合理估值。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0010","BK1161","BK4585","688235","BK1588","BK4548","06160","BK4526","BK1583","BK0239","BK4535","BK0188","BK4139","BK4588","02268","BK0185","LU0307460666.USD","BK1500","BK0175","BK4505","LU1969619763.USD","BK0028","BK0250","BK0082","LU0588546209.SGD","600056","BGNE","LU2328871848.SGD","BK4504","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2490684727","title":"野村料中国医药行业明年首季及上半年收入增速可回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2490684727","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490684727?lang=zh_cn&edition=full","pubTime":"2024-12-12 10:46","pubTimestamp":1733971560,"startTime":"0","endTime":"0","summary":"野村中国医药保健行业研究部主管张佳林指，今年中国医疗市场仍面对困境，等待复苏。他预期，在低基数及潜在需求逐步释放下，明年首季及上半年行业收入增长将重新加快，看好GLP-1新药及抗体偶联药物ADC等前景，又指行业估值处于较低水平，亦为未来的反弹提供基础，在生物科技股中较看好百济神州，认为其海外市场特别是美国地区销售表现强劲，而在CRO板块则看好药明合联的高增长潜力及合理估值。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20241212104517669_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20241212104517669_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1403629&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["600056","BK0010","BK0185","BK0188","BK0250","BK0175","BK0082","BK0028"],"gpt_icon":0},{"id":"2490837482","title":"中国医药：公司股票今日收涨。公司目前生产经营活动正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2490837482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490837482?lang=zh_cn&edition=full","pubTime":"2024-12-11 19:00","pubTimestamp":1733914840,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药(600056)12月11日在投资者关系平台上答复投资者关心的问题。投资者：中国医药有问题吗？为什么一直不涨，第一医药涨停了。中国医药董秘：尊敬的投资者您好，公司股票今日收涨。公司目前生产经营活动正常。二级市场股价波动受到宏观经济、行业政策、市场环境等诸多因素影响，敬请广大投资者注意投资风险。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121100031805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0082","BK0175","BK0010","BK0185","BK0028","600056","BK0188"],"gpt_icon":0},{"id":"2489746697","title":"中国医药12月05日主力资金流出2061万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2489746697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489746697?lang=zh_cn&edition=full","pubTime":"2024-12-05 15:19","pubTimestamp":1733383149,"startTime":"0","endTime":"0","summary":"12月05日, 中国医药股价跌0.17%，报收11.70元，成交金额1.80亿元，换手率1.03%，振幅1.02%，量比0.65。中国医药今日主力资金净流出2061万元，连续3日净流出，上一交易日主力净流出1125万元，今日环比增加83.20%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为42.86%，平均跌幅为1.43%。该股近5个交易日上涨0.09%，主力资金累计净流出3890万元；近20日主力资金累计净流出2.26亿元，其中净流出天数为13日。净流出前三个股分别为老百姓、中国医药、海王生物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205152737a1d5b169&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205152737a1d5b169&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0010","BK0188","BK0082","BK0175","BK0185","BK0028","BK0250","600056"],"gpt_icon":0},{"id":"2488151491","title":"中国医药最新公告：子公司天方药业获得磷酸奥司他韦胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2488151491","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488151491?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:49","pubTimestamp":1733302170,"startTime":"0","endTime":"0","summary":"中国医药公告，公司全资子公司天方药业收到国家药监局核准签发的磷酸奥司他韦胶囊《药品注册证书》。该药品主要用于成人和1岁及1岁以上儿童的甲型和乙型流感治疗，用于成人和13岁及13岁以上青少年的甲型和乙型流感的预防。此次获得药品注册证书，有利于丰富公司产品线，但未来可能受国家政策、市场环境等不确定因素影响，存在销售不达预期等情况。该药品累计投入约964万元人民币。国内已有38家生产企业获批该药品上市，共有57个批准文号。2023年该药品国内样本医院销售额约为2.66亿元，2024年前两个季度为2.12亿元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400028920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0010","BK0175","BK0028","600056","BK0250","BK0188","BK0082"],"gpt_icon":0},{"id":"2488518931","title":"中国医药(600056.SH)：磷酸奥司他韦胶囊获药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2488518931","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488518931?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:47","pubTimestamp":1733302037,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)公告，近日，公司下属全资子公司天方药业有限公司(简称“天方药业”)收到国家药品监督管理局(简称“国家药监局”)核准签发的一份磷酸奥司他韦胶囊《药品注册证书》。据悉，磷酸奥司他韦是其活性代谢产物(奥司他韦羧酸盐)的前体药物，奥司他韦羧酸盐是选择性的流感病毒神经氨酸酶抑制剂。磷酸奥司他韦主要用于成人和1岁及1岁以上儿童的甲型和乙型流感治疗，用于成人和13岁及13岁以上青少年的甲型和乙型流感的预防。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0188","600056","BK0175","BK0185","BK0028","BK0250","BK0082"],"gpt_icon":0},{"id":"2488962593","title":"新康界：2024年1-8月中国医药零售市场药品销售规模达到3244亿元 同比增长1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488962593","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488962593?lang=zh_cn&edition=full","pubTime":"2024-12-03 15:56","pubTimestamp":1733212580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据新康界数据，2024年1-8月，中国医药零售市场的药品销售规模达到3244亿元，同比增长1.4%。分渠道来看，零售药店规模占比为87.0%， 同比增速为0.3%；电商B2C规模占比为13.0%，同比增速达9.6%，规模占比同比提升1.0%，渠道重要性提升。电商B2C增速除2024年2月外均快于零售药店，为中国医药零售市场的增长驱动;截至2024年8月，电商B2C规模达422亿元，增速为9.6%，糖尿病用药表现突出，增速超群。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0010","BK0175","BK0028","600056","BK0250","BK0188","BK0082"],"gpt_icon":0},{"id":"2488626508","title":"中国医药最新公告：子公司天方药业获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2488626508","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488626508?lang=zh_cn&edition=full","pubTime":"2024-12-02 17:00","pubTimestamp":1733130050,"startTime":"0","endTime":"0","summary":"中国医药公告，其全资子公司天方药业收到国家药监局签发的两份盐酸托莫西汀胶囊《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。通知书同意增加25mg规格，核发药品批准文号，通过仿制药质量和疗效一致性评价。该药品用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)，2023年国内公立医院及公立基层医疗终端销售额约为3.18亿元，2024年上半年销售额约为1.51亿元。公司该药品2023年销售额约为59万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120200021482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0188","BK0082","BK0175","BK0185","BK0028","BK0250","600056"],"gpt_icon":0},{"id":"2488356626","title":"中国医药(600056.SH)子公司盐酸托莫西汀胶囊通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2488356626","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488356626?lang=zh_cn&edition=full","pubTime":"2024-12-02 17:00","pubTimestamp":1733130036,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司天方药业有限公司(简称“天方药业”)收到国家药品监督管理局核准签发的两份盐酸托莫西汀胶囊《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。盐酸托莫西汀胶囊用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)。目前原研产品已国内进口上市。根据国家相关政策，通过一致性评价的药品品种在医保支付及医疗机构采购等领域将获得更大的支持力度。天方药业的盐酸托莫西汀胶囊通过仿制药质量和疗效一致性评价，有利于扩大该药品的市场份额。同时，为公司后续产品开展仿制药一致性评价工作积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0185","BK0028","BK0250","BK0188","BK0175","BK0010","600056","BK0082"],"gpt_icon":0},{"id":"2488666628","title":"中国医药12月02日主力资金流入982万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2488666628","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488666628?lang=zh_cn&edition=full","pubTime":"2024-12-02 15:17","pubTimestamp":1733123862,"startTime":"0","endTime":"0","summary":"12月02日, 中国医药股价涨1.44%，报收11.96元，成交金额2.99亿元，换手率1.68%，振幅1.70%，量比0.99。中国医药今日主力资金净流入982万元，连续3日净流入，上一交易日主力净流入1031万元，今日环比减少4.75%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为60.00%，平均涨幅为1.54%。该股近5个交易日上涨2.84%，主力资金累计净流出935万元；近20日主力资金累计净流出1.77亿元，其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202151926a26594a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202151926a26594a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0250","BK0185","600056","BK0082","BK0028","BK0010","BK0188"],"gpt_icon":0},{"id":"2487335185","title":"中国医药(600056.SH)：胞磷胆碱钠注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2487335185","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487335185?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:13","pubTimestamp":1732871638,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，公司下属全资子公司天方药业有限公司(简称“天方药业”)收到国家药品监督管理局核准签发的三份胞磷胆碱钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。胞磷胆碱钠注射液为细胞代谢改善药，用于急性颅脑外伤及脑手术后的意识障碍。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0188","BK0082","BK0010","600056","BK0175","BK0250","BK0185","BK0028"],"gpt_icon":0},{"id":"2487380185","title":"中国医药最新公告：子公司天方药业胞磷胆碱钠注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2487380185","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487380185?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:10","pubTimestamp":1732871435,"startTime":"0","endTime":"0","summary":"中国医药公告称，其全资子公司天方药业收到国家药监局核准签发的三份胞磷胆碱钠注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。胞磷胆碱钠注射液为细胞代谢改善药，用于急性颅脑外伤及脑手术后的意识障碍。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112900025671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0250","BK0185","600056","BK0082","BK0028","BK0010","BK0188"],"gpt_icon":0},{"id":"2486239432","title":"中国医药最新公告：重要参股公司筹划变更实际控制人事项获得重庆市国资委批复","url":"https://stock-news.laohu8.com/highlight/detail?id=2486239432","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486239432?lang=zh_cn&edition=full","pubTime":"2024-11-28 18:50","pubTimestamp":1732791045,"startTime":"0","endTime":"0","summary":"中国医药公告，公司收到重庆医药《关于化医集团的报告》，重庆化医集团已取得重庆市国有资产监督管理委员会出具的批复，同意将所持重庆医药2%股权无偿划转给通用技术集团。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800030462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0028","BK0082","BK0250","BK0185","BK0188","BK0010","BK0175"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600721","603108","BK0185","688163","603087","600976","600351","603858","600436","603939","688575","600380","600998","688331","603309","688266","600200","688278","600055","605199","603392","600161","600521","BK0070","600572","688192","688276","603439","600771","688506","688315","603567","600511","BK0096","688298","688356","600329","688193","600332","688581","688180","688336","600851","688076","688139","688198","600196","603127","600085","600129","688656","600080","603301","603658","600566","688373","688189","688067","605177","BK0012","600867","688221","688050","688488","688578","688687","688212","688105","688301","688670","600056","688046","688382","688091","688389","603456","688062","688085","603707","688566","600739","688235","688247","688428","600079","600062","688520","600763","603882","BK0239","688177","159938","603259","600252","603538","603896","688029","600420","688117","688658","688073","688351","BK0188","688222","688137","601607","688202","603590","600422","600535","688626","BK0028","688114","688176","600529","688690","600276","688443","600211","600285","688617","688767","688271","688321","688166","603367","603233","688161","600488"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","stockEarnings":[{"period":"1week","weight":-0.0567},{"period":"1month","weight":-0.0505},{"period":"3month","weight":0.1949},{"period":"6month","weight":0.146},{"period":"1year","weight":0.0709},{"period":"ytd","weight":0.067}],"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","perCapita":"9752股","boardName":"批发业","registeredCapital":"149587万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 中国医药健康产业股份有限公司建立了以国际贸易为引领、以医药工业为支撑、以医药商业为纽带的贸、工、技、服一体化产业格局，全面推动工商贸三大业务板块业务整合，积极发挥协同优势。主要产品有原料药、制剂药、中成药、医药商业、国际贸易。公司在中国物流与采购联合会医疗器械供应链分会发布的“2023年中国医疗器械供应链百强企业”中位列第5位；在“2023年中国医疗器械SPD运营服务商重点企业”中位列第11位。","serverTime":1734636405413,"listedPrice":7.02,"stockholders":"153324人(较上一季度减少3.74%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}